Prof Michael Michael
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
349 Scholarly works
15 Projects
HIGHLIGHTS
2025
Journal article
Role of Neoadjuvant Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer: A Systematic Review of Currently Available Studies
DOI: 10.1097/DCR.00000000000039272025
Journal article
Real-World Outcomes Between Perioperative Chemotherapy (FLOT) and Preoperative Concurrent Chemoradiotherapy (CROSS) in Localized Esophageal and Esophagogastric Junction Adenocarcinoma: A Retrospective Cohort Study
DOI: 10.3390/cancers171829622025
Journal article
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
DOI: 10.1007/s00259-025-07235-w2025
Journal article
Neoadjuvant intraperitoneal chemotherapy in high-risk and cytology positive gastric cancer: a systematic review
DOI: 10.1016/j.suronc.2025.1022372023
Research grants (ARC, NHMRC, MRFF)
PRECISION\2013 Pharmacogenomic Medicines Optimisation for People With Cancer
2020
Research Grant
The Preclinical Validation of Radio-Labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer
2018
Research Grant
Mechanisms of Resistance to Immunological Targeting of Primary and Metastatic Colorectal Cancers
RECENT SCHOLARLY WORKS
2025
Journal article
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial
DOI: 10.1002/bcp.700062025
Journal article
Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
DOI: 10.1016/j.eclinm.2025.1031612025
Journal article
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
DOI: 10.1111/jne.134612025
Journal article
Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world registry data from an Australian population
DOI: 10.1186/s12889-025-23925-42024
Journal article
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial
DOI: 10.1111/cts.700832024
Conference Proceedings
Mutated KRASas a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment
DOI: 10.1200/jco.2024.42.16_suppl.11150
RECENT PROJECTS
2025
Research grants (ARC, NHMRC, MRFF)
Trial Implementation of Pharmacogenomics to Improve Complex Hospital Care
2021
Research grants (ARC, NHMRC, MRFF)
AGITG TOP GEAR: A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer